Sumatriptan Teva
A marketed medicine name used in several European markets for film-coated tablets containing sumatriptan. Product names, authorisation holders, strengths and dispensing status are stored by market rather than assumed globally.
Product snapshot
Verified market example: Finland
- Active ingredient
- Sumatriptan →
- Strengths
- 50 mg · 100 mg
- Dosage form
- Film-coated tablet
- Market
- Finland
- MA holder
- Teva Sweden AB
- Route
- Oral
Product identity
What exactly is this page describing?
Sumatriptan Teva is treated here as a marketed product-family name, not as a synonym for the active ingredient. The same underlying Teva product family is labelled differently across European markets; for example, current Finnish records use “Sumatriptan Teva,” while UK Teva product information is titled “Sumatriptan 50 mg / 100 mg Film-coated Tablets.”
Active ingredient
This product contains sumatriptan
Sumatriptan
Evidence, mechanism, general safety and cross-product medicine information belong primarily to the active-ingredient profile rather than being duplicated as claims about this commercial product.
View Sumatriptan reference →Authorised use
What is the product used for?
Official product information for Sumatriptan Teva 50 mg in Spain states an indication for the acute treatment of migraine attacks with or without aura. UK Teva product information for the corresponding 50 mg and 100 mg film-coated tablets likewise describes acute migraine treatment and not prophylactic use.
The wording shown to users should ultimately be selected from the regulatory record for the chosen country.
Presentations
Verified strengths and market records
The page is one product-family node linked to multiple jurisdiction-specific records.
| Market | Product name | Strength / form | Regulatory holder |
|---|---|---|---|
| Finland | Sumatriptan Teva | 50 mg and 100 mg · film-coated tablet | Teva Sweden AB |
| Spain | Sumatriptán Teva | 50 mg · film-coated tablet | Teva regulatory record |
| United Kingdom | Sumatriptan Film-coated Tablets | 50 mg and 100 mg | Teva UK Limited |
Regulatory information
Product facts are sourced by jurisdiction
- Finland MA numbers
- 22891 (50 mg) · 22892 (100 mg)
- Finland status
- Marketing authorisation granted; marketed packages listed by Fimea
- Spain product code
- CIMA record 68727 (50 mg)
- UK Teva PIL
- PL 00289/0588 · PL 00289/0589
- WHO ATC code
- N02CC01 · Sumatriptan
Evidence layer
Clinical evidence is assessed at the active-ingredient and indication level
This product contains sumatriptan. DiseasesConditions should not convert evidence about the active ingredient into a claim that a particular commercial brand has independently “proven efficacy” unless the evidence specifically evaluates that product or formulation.
The active-ingredient page is the canonical location for general evidence, mechanism, safety and interaction context.
Product safety
Safety must follow the exact product record
Product-specific information can include excipients, tablet appearance, storage requirements, pack sizes and jurisdiction-specific warnings. For example, current Teva product information lists lactose among the excipients for these film-coated tablets. General sumatriptan contraindications and interactions belong on the active-ingredient reference, with product-specific differences added here when relevant.
Same active ingredient
Find products containing sumatriptan
Use Medicine Search to connect a marketed product to its active ingredient and find related medicine records across markets.
Products containing the same active ingredient are not necessarily interchangeable. Strength, dosage form, route and regulatory status may differ.
Independent reference
Brand and product names are used for identification
DiseasesConditions is an independent medical reference and is not affiliated with or endorsed by Teva or other manufacturers and trademark owners listed in product records. Product and brand names are used to identify medicines and connect them to active ingredients, regulatory records and evidence.
Sources & provenance
Regulatory records
- Fimea — medicinal products databaseCurrent Finnish Sumatriptan Teva 50 mg / 100 mg product records, strengths, form and MA holder.
- AEMPS CIMA — Sumatriptán Teva 50 mg SmPCSpanish product name, composition, dosage form and therapeutic indication.
- Teva UK — Sumatriptan 50 mg / 100 mg patient leafletUK strengths, dosage form, authorisation holder, product numbers and EEA naming information.
Last source check: 24 September 2026. Market status can change; final product pages should retain source dates and jurisdiction-specific records.